Long-term survival estimates for imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

Cost-effectiveness of imatinib versus in

Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

✍ Shelby D. Reed; Kevin J. Anstrom; Jennifer A. Ludmer; G. Alastair Glendenning; K 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 1 views

## Abstract ## BACKGROUND Despite a lack of long‐term data, imatinib has become standard therapy for patients with newly diagnosed chronic‐phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the increment